Comparing the current results to its competitors, Evofem Biosciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by -45.43 %, despite the revenue increase by the most of its competitors of 4.63 %, recorded in the same quarter.
Evofem Biosciences Inc 's Comment on Competition and Industry Peers
PHEXX is positioned to compete in the market for hormonal short-acting reversible contraceptives, including oral contraceptive pills, patches, injectables, and rings, as well as long-acting reversible contraceptives such as intrauterine devices (IUDs) and implants. The company holds ownership or exclusive licenses to patents related to SOLOSEC, which serve as barriers to competitor entry. The trademarks EVOFEM, PHEXX, SOLOSEC, and FEMIDENCE are owned by Evofem Biosciences, Inc. Evofem Biosciences, Inc. is identified as a competitor in related filings.
October 8, 2024
Navigating Health Innovation: Aditxt s Strategic Investment in Evofem Biosciences In a significant move reflecting the dynamism of the biotech industry, Aditxt, Inc. (NASDAQ: ADTX) has successfully completed its third Parent Equity Investment under the Amended and Restated Merger Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM). This development not only reinforces the bond between two forward-thinking entities but also signifies a renewed commitment to enhancing health innovations, particularly in the realm of women s health.Aditxt, based in Mountain View, California, has carved a niche for itself as an innovation platform dedicated to propelling promising health technologies forward. The company s str...
September 23, 2024
In a significant move for the advancement of women’s health diagnostics, Aditxt, Inc. (NASDAQ: ADTX) has solidified its position in the biotechnology landscape through strategic collaborations with Evofem Biosciences, Inc. (OTCQB: EVFM). The oncology-focused company is leveraging its majority-owned subsidiary, Pearsanta, Inc. (Pearsanta), to develop a blood-based diagnostic test for endometriosis, which is expected to hit the U.S. market by mid-2025. Partnership InsightsOn a foundational level, the Market Development Collaboration Agreement between Pearsanta and Evofem is a testament to the shared vision of both companies to address a significant gap in the diagnosis of endometriosis. This condition affect...
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Oncolytics Biotech Inc operates as a biotechnology company engaged in the development and commercialization of oncolytic viruses as potential therapeutics for the treatment of various cancers. Its business model revolves around identifying and acquiring intellectual property rights, conducting preclinical and clinical studies, and collaborating with pharmaceutical and biotechnology companies for the development and commercialization of its products. The company aims to deliver innovative and targeted cancer therapies to improve patient outcomes globally.
Hologic Incs business model focuses on developing and commercializing medical technologies and diagnostic products, primarily dedicated to womens healthcare. Their offerings include innovative solutions for breast and skeletal health, gynecological health, and surgical products, aiming to improve patient outcomes and enhance healthcare practices.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for the treatment of various types of cancer. Their business model revolves around conducting extensive research and development to identify and validate potential drug candidates, followed by clinical trials to assess their safety and efficacy. Additionally, they collaborate with other companies and organizations to advance their therapies and bring them to market.
Sources:
Evofem Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Evofem Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
